MB-111

N/A

Report date: 2025/08/29 17:06:05

Base Information

Drug NameMB-111
Drug Alias NameMB-111
ClassificationCell and gene therapy > Gene therapy > LNPCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionApolipoprotein C-III inhibitorsGene transference
TargetsApolipoprotein C-IIIFibroblast growth factor 2
Therapy Area/IndicationsHypertriglyceridemiaHyperlipoproteinemia Type I
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMammoth Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesMammoth Biosciences Inc
Inactive CompaniesN/A
Active IndicationsHypertriglyceridemiaHyperlipoproteinemia Type I
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A